SCHEMBL2239236

SCHEMBL2239236

Cc1ccc(S(=O)(=O)N[C@@H](c2ccccc2)C(N)c2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
NPSR1 Q6W5P4 4/20 0.53
SLC1A3 P43003 1/20 0.51
SLC1A2 P43004 1/20 0.51
SLC1A1 P43005 1/20 0.51
HTT P42858 2/20 0.49
CA12 O43570 3/20 0.49
CA9 Q16790 3/20 0.49
CA2 P00918 2/20 0.49
CA1 P00915 1/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
LMNA P02545 2/20 0.47
MAPT P10636 1/20 0.47
HPN P05981 2/20 0.47
PLAU P00749 1/20 0.47
CA7 P43166 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
GAA P10253 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130104 1.00 ALDH1A1 (0.53) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
SCHEMBL1464202 1.00 ALDH1A1 (0.53) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
SCHEMBL10193067 1.00 ALDH1A1 (0.53) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
SCHEMBL29500256 1.00 ALDH1A1 (0.53) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
SCHEMBL472429 1.00 ALDH1A1 (0.53) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
SCHEMBL292958 1.00 ALDH1A1 (0.53) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
SCHEMBL258422 1.00 ALDH1A1 (0.53) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
SCHEMBL13050357 1.00 ALDH1A1 (0.53) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
SCHEMBL7089968 0.98 ALDH1A1 (0.52) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
P-Xylene SCHEMBL5424500 0.98 ALDH1A1 (0.52) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2868659-B1 Method for producing optically active naphthalene compound MITSUBISHI TANABE PHARMA CORP (JP) 2016-05-04 EP claimed
US-9181217-B2 Method for producing optically active naphthalene compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-11-10 US claimed
US-20150152082-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE NAPHTHALENE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-06-04 US claimed
EP-2868659-A1 Method for producing optically active naphthalene compound Mitsubishi Tanabe Pharma Corporation (JP) 2015-05-06 EP claimed
EP-2749558-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE NAPHTHALENE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2014-07-02 EP claimed
US-20260125380-A1 PRMT5 INHIBITORS AND METHODS OF USE SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2026-05-07 US disclosed
EP-4592289-A1 NOVEL PRMT5 INHIBITOR AND USE THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2025-07-30 EP disclosed
US-20250051331-A1 PRMT5 INHIBITORS AND METHODS OF USE SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2025-02-13 US disclosed
US-12173002-B2 PRMT5 inhibitors and methods of use SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2024-12-24 US disclosed
US-20240294528-A1 PRMT5 INHIBITORS AND METHODS OF USE SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2024-09-05 US disclosed
US-9382280-B2 Diamine compound and metal complexes, and method for producing optically active compounds TAKASAGO INTERNATIONAL CORPORATION (JP) 2016-07-05 US disclosed
EP-2868659-B1 Method for producing optically active naphthalene compound MITSUBISHI TANABE PHARMA CORP (JP) 2016-05-04 EP disclosed
EP-1944291-B1 Optically active cyclic alcohol compound and method for producing same MITSUBISHI TANABE PHARMA CORP (JP) 2012-06-13 EP disclosed
EP-2371820-A1 Optically active cyclic alcohol compound and method for preparing the same Mitsubishi Tanabe Pharma Corporation (JP) 2011-10-05 EP disclosed
US-20110196157-A1 OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME MITSUBISHI TANABE PHARMA CORPORATION 2011-08-11 US disclosed
US-20100152451-A1 OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-17 US disclosed
US-20100048537-A1 HETEROARYL DERIVATIVES NIPPON SHINYAKU CO., LTD. (JP) 2010-02-25 US disclosed
EP-2141168-A1 HETEROARYL DERIVATIVES Nippon Shinyaku Co., Ltd. (JP) 2010-01-06 EP disclosed
EP-1944291-A1 OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PRODUCING SAME Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-16 EP disclosed
JP-2000016954-A PRODUCTION OF OPTICALLY ACTIVE 1,2-DIOLS MITSUBISHI CHEMICALS CORP 2000-01-18 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12173002-B2 PRMT5 inhibitors and methods of use PRMT5, PRMT1, PRMT7 ALDH1A1 3578/4885NPSR1 3874/4885SLC1A3 1336/4885
US-20150152082-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE NAPHTHALENE COMPOUND HRH1, HRH4, RB1 ALDH1A1 343/4885NPSR1 595/4885SLC1A3 4437/4885
US-20250051331-A1 PRMT5 INHIBITORS AND METHODS OF USE PRMT5, PRMT1, PRMT7 ALDH1A1 3523/4885NPSR1 3985/4885SLC1A3 872/4885
US-20110196157-A1 OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME ADH1C, ADH1A, ADH5 ALDH1A1 25/4885NPSR1 3303/4885SLC1A3 3110/4885
US-20100152451-A1 OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME ADH1C, ADH1A, ADH5 ALDH1A1 25/4885NPSR1 3303/4885SLC1A3 3110/4885
US-20100048537-A1 HETEROARYL DERIVATIVES OPRD1, OPRM1, OPRK1 ALDH1A1 66/4885NPSR1 13/4885SLC1A3 454/4885
US-20260125380-A1 PRMT5 INHIBITORS AND METHODS OF USE PRMT1, PRMT5, PRMT6 ALDH1A1 4399/4885NPSR1 3839/4885SLC1A3 2197/4885
US-20240294528-A1 PRMT5 INHIBITORS AND METHODS OF USE PRMT5, PRMT1, PRMT3 ALDH1A1 3659/4885NPSR1 3471/4885SLC1A3 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.